Adama will license Australian company Starpharma’s Priostar dendrimer technology for the development and commercialization of an enhanced, proprietary 2,4-D herbicide for the U.S. market, the companies announced.
El mercado de 2,4-D de EE. UU. En 2014 valía aproximadamente $115 millones, y el Departamento de Agricultura de EE. UU. Ha proyectado que crecerá en más de 70% para 2020.
Adama ya ha comenzado el desarrollo de un producto 2,4-D novedoso y único que contiene la tecnología dendrímero Priostar, que se espera que brinde una mayor flexibilidad y beneficios de control de malezas al cultivador, así como una mayor seguridad. Esto permitirá una aplicación en el objetivo, beneficiando así al medio ambiente al reducir las cantidades de producto requeridas.
Sami Shabtai, Head of Innovative Development at Adama, commented, “As a farmer-centric company, Adama constantly strives to bring new and innovative solutions to farmers that will simplify their lives. The innovative nature and superior performance of the Priostar formulations fit well with our strategy to deliver simple and efficient solutions to farmers to help them grow. This is yet another step in the evolution and differentiation of our offering, as we continue to introduce unique mixtures and formulations to the market.”
Dr. Jackie Fairley, CEO of Starpharma, said, “We enjoy a positive relationship with Adama, and their extensive trials of Priostar-improved 2,4-D formulations have led to this license agreement. With Adama’s strong, proven record of innovative product development, we are very pleased to have them as commercial partners for Priostar-improved 2,4-D products. In addition, we continue to explore other Priostar product opportunities with Adama.”